HOUSE_OVERSIGHT_013482.txt

This document discusses stem cell therapy in the United States and Europe. In the US, President Obama overturned an executive order prohibiting federal funding of human embryonic stem cell research, leading to increased momentum in this field. The first regulatory approval of a manufactured stem cell product has also been achieved. However, there are still challenges, such as a tough regulatory climate for biopharmaceuticals and legal challenges to the relaxing of rules on hESCs. In Europe, experts debate what must be done to maintain its lead in regenerative medicine and stem cell research.